China Medical University (CMU) and its Healthcare System have been recognized with 17 awards at the 2024 Taiwan National Innovation Awards for pioneering advancements in biotechnology, smart healthcare, and innovative medical devices. The awards highlight CMU's role as a leader in transforming healthcare through cutting-edge research and development.
CAR001 Cell Therapy Shows Promise
A significant achievement is the development of CAR001 cell therapy by Ever Supreme Bio Technology, a CMU spin-off company. This therapy utilizes allogeneic CAR and BiTE-GDT technologies to precisely target solid tumors. The research team employed artificial intelligence to identify HLA-G as a critical target, enabling the development of the CAR001 (CAR-T) technique.
Preclinical Success and Clinical Trials
In preclinical animal trials, CAR001 achieved a 90% tumor eradication rate. These results have been published in leading medical journals. The therapy has received Phase I and IIa clinical trial approvals in both Taiwan and the United States, marking a significant step toward clinical application and offering new hope for patients with solid tumors.
AI and Exosome Technology
CMU and its Healthcare System are also pioneering the use of artificial intelligence in various critical areas, including drug discovery, myocardial infarction treatment, infection and sepsis management, remote dialysis, image analysis, and medical education. Additionally, they are advancing exosome-based technology, offering solutions for cancer and neurodegenerative diseases like Parkinson's. The precision of their targeted exosome delivery system significantly enhances treatment outcomes.
